Regulatory Beat

Apr 01, 2014
BioPharm International
New identifiers and tracking requirements aim to block illegitimate products.
Mar 01, 2014
BioPharm International
Manufacturers are taking measures to comply with new package safety rules.
Feb 01, 2014
BioPharm International
High technology assessments are having an impact on biosimilars development in Europe.
Dec 01, 2013
BioPharm International
New policies and products seek to maintain access to pain medicines while curbing rampant abuse.
Nov 01, 2013
BioPharm International
Legislators agree on a limited bill affirming FDA authority over compounders while setting up a process for national drug tracking.
Oct 01, 2013
BioPharm International
Manufacturing standards are considered key to preventing drug recalls and shortages.
Sep 01, 2013
BioPharm International
New FDA supply chain policies aim to strengthen inspection and oversight processes.
Sep 01, 2013
BioPharm International
The aim of the European Falsified Medicines Directive is to improve the quality of imported APIs, but does the pain now outweigh the gain?
Sep 01, 2013
BioPharm International
Updates on user fees, heparin supply concerns, orphan drug incentives, REMS updates, reference standards for proteins, and patent settlements.
Aug 01, 2013
BioPharm International
FDA funds research to further development of innovative generics, while working to address review and approval issues.
native1_300x100
lorem ipsum